# HERG Screening Market > HERG Screening Market Research Report Information By Type (Gene KCNH2 and Mutant KCNH2), By Ion Channel (Voltage Gated and Ligand Gated), By Application (Antiarrhythmic, Antipsychotic, Antibiotics, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 11.04% - **2024:** $ 1.12 Billion - **2025:** $ 1.24 Billion - **2035:** $ 3.54 Billion - **Key Players:** Thermo Fisher Scientific (US), Charles River Laboratories (US), Evotec SE (DE), Celerion (US), Crown Bioscience (US), BioAgilytix (US), Inotiv (US), Haplogen (US) **Report ID:** MRFR/HC/8908-CR · **Pages:** 107 · **Author:** Vikita Thakur & Kinjoll Dey · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/herg-screening-market-10386 --- ## Market Summary ## **Global HERG Screening Market Overview** HERG Screening Market Size was valued at USD 1.0 Billion in 2023. The HERG Screening market is projected to grow from USD 1.12 Billion in 2024 to USD 2.6 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.04% during the forecast period (2024 - 2032).The rising approval of innovative drugs and the rise in heart disease prevalence, are the key market drivers enhancing the market growth.  _Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review_ ## **HERG Screening Market Trends** As heart disease prevalence and the number of heart condition patients both rise, the market is expected to grow. The market is growing as a result of increased R&D activities in support of new product releases. Additionally, it is projected that a rise in the number of innovative drug entity approvals will support the market's growth. The market is growing as a result of both the creation of remedies for illnesses and disorders and the rise in demand for drug formulations. Growing challenges in producing biotechnological or pharmaceutical goods based on the application are also creating more opportunities for the growth of the HERG screening market. Due to the growth in instances of cardiotoxicity, there has been a significant demand for screening the materials used in pharmaceutical production. Traditional testing methods may not always be better than HERG tests, but they may be safer and more successful when used on medications. Cardiovascular drugs are increasingly having adverse side effects in patients with pre-existing heart conditions. Cardiotoxicity is more common in patients who have had cancer treatment or cardiac surgery. Consequently, there is a rising demand for equipment and services that enable efficient cardiotoxicity testing. The heart has a harder time carrying out normal functions and distributing blood throughout the body when there is cardiotoxicity. Cardiotoxicity consequently increases the risk of cardiomyopathy, which reduces the heart's capacity to pump blood. Heart disease is the top cause of death for both men and women worldwide. According to the American College of Cardiology, an American will experience a myocardial infarction every 40 seconds. Emergency medical services reported that 356,461 Americans had cardiac arrest outside of a hospital in 2017, and in 52% of those cases, emergency medical services treatment was started. Only 18.7% of the patients had ventricular fibrillation or ventricular tachycardia at the start of their treatment, which might have been shocked by an AED. 10.4% of adults survived after leaving the hospital, and 8.4% of them had satisfactory functional status. Sedentary habits and common risk factors, such as hypertension (which can range from 28% in the United Arab Emirates to 41% in Libya and Morocco), diabetes (which can range from 4% in the Islamic Republic of Iran to 19% in Sudan), and hypercholesterolemia (which can range from 14% in Lebanon to 52% in the Islamic Republic of Iran), are to blame for the prevalence of cardiovascular diseases. The market for [drug discovery](../../../reports/drug-discovery-services-market-5870) will expand as a result of the rise in heart disease, boosting the expansion of the HERG screening industry.Thus, driving the HERG Screening market revenue. ## **HERG Screening Market Segment Insights** ### **HERG Screening Type Insights** The HERG Screening market segmentation, based on Type, includes Gene KCNH2 and Mutant KCNH2. Gene KCNH2 segment dominated the market in 2022. This channel is especially important for the generation and transmission of electrical impulses as it is in charge of removing positively charged potassium atoms from the cells. This is so that it can move the atoms of potassium. The KCNH2 gene is in charge of controlling and supplying the necessary instructions for the production of potassium channels. The main reason causing the ultimate emergence of cardiac [arrhythmia](../../../reports/arrhythmia-monitoring-devices-market-6714) was the KCNH2 mutation. ### **HERG Screening Ion Channel Insights** The HERG Screening market segmentation, based on Ion Channel, includes Voltage Gated and Ligand Gated. Voltage Gated segment dominated the HERG Screening market in 2022.The members of the voltage-gated ion channel family that regulate the open and closed states of the cell membrane potential include Na+, Ca+, and K+. The ionic gradients required for regular cell activity are maintained by these channels in a variety of cell types, including neurons, heart muscle, and skeletal muscle. The movement of ions across cell membranes is tightly regulated by these channels. ### **HERG Screening Application Insights**  The HERG Screening market segmentation, based on Application, includes Antiarrhythmic, Antipsychotic, Antibiotics, and Others. Antiarrhythmic segment dominated the market in 2022. Antiarrhythmic medications are used to treat symptomatic tachycardias and premature beats. These can be administered intravenously in an emergency or orally for long-term treatment. These drugs either prevent aberrant pacemaker tissue firing or reduce the speed at which impulses are transmitted in tissues that conduct too quickly or engage in reentry. The use of these assays for arrhythmia treatment, scientific investigations into the safety and effectiveness of HERG screening, and an increase in cardiovascular diseases globally are all factors propelling the market's growth. **Figure 1: HERG Screening Market, by Application, 2022 & 2032 (USD Billion)**  Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ### **HERG Screening Regional Insights** By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America HERG Screening Market dominated this market in 2022 (45.80%). Every 40 seconds, a citizen of the United States will experience a myocardial infarction, according to the American College of Cardiology. In 2017, 356,460 Americans went through an out-of-hospital cardiac arrest, and in 52% of those cases, emergency medical services were called.Further, the U.S. HERG Screening market held the largest market share, and the Canada HERG Screening market was the fastest growing market in the North America region. Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. **Figure 2: ****HERG Screening Market Share By Region 2022 (USD Billion)** Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review Europe HERG Screening market accounted for the healthy market share in 2022. Europe's western and eastern regions make up the majority of the market for HERG screening and are both regarded as major contributors.Further, the German HERG Screening market held the largest market share, and the U.K HERG Screening market was the fastest growing market in the European region. The Asia Pacific HERG Screening market is expected to register significant growth from 2024 to 2032. A significant portion of the people in the area have chronic heart conditions, and the incidence of inflammatory disorders is rising quickly as well. Moreover, China’s HERG Screening market held the largest market share, and the Indian HERG Screening market was the fastest growing market in the Asia-Pacific region. **HERG Screening Key Market Players & Competitive Insights** Leading market players are investing heavily in research and development in order to expand their product lines, which will help the HERG Screening market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, HERG Screening Industry must offer cost-effective items. Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the HERG Screening Industry to benefit clients and increase the market sector. In recent years, the HERG Screening Industry has offered some of the most significant advantages to medicine. Major players in the HERG Screening market, including Charles River Laboratories, Eurofins Scientific, Merck KGaA, Cyprotex Limited, BSYS GmbH, Creative bioarray, Metrion biosciences, and Aurora Biomed, are attempting to increase market demand by investing in research and development operations. Charles River Laboratories International Inc. (Charles River), a contract research organisation (CRO), provides essential products and services to speed up analysis, medication discovery, and development. It offers a variety of services for fundamental research, drug discovery, and safety assessment. The company also offers assistance with production, operations, and employment. It provides treatments for conditions affecting the cardiovascular, nervous, metabolic, inflammatory, pulmonary, musculoskeletal, and oncological systems. Charles River provides services to prestigious hospitals, universities, government agencies, pharmaceutical and biotechnology companies, and other clientele. The headquarters of Charles River are located in Wilmington, Massachusetts, a city in the US. Analytical testing services are provided to clients in a variety of industries by a life sciences company called Eurofins Scientific SE (Eurofins). The company offers a variety of services including forensics, environmental testing, agroscience, biopharma, pharmaceutical discovery, early development, pharmaceutical central laboratory, biopharma product testing, and product testing. Its analytical methods help in figuring out whether biological products and chemicals are pure, real, and safe. It draws on its knowledge in logistics and information technology to offer a range of services. The company has activities in North America, South America, the Middle East, Asia Pacific, and Europe. Eurofins' main office is in Luxembourg. In July 2017, Eurofins Scientific purchased Discover X, a market leader in drug discovery technologies and services from target identification and lead discovery to preclinical and beyond. **Key Companies in the HERG Screening market include** **HERG Screening Industry Developments** _**March 2020:**__An alliance was formed between Charles River Laboratories and Deciphex, a pioneer in preclinical digital pathology software-as-a-service. The organisations will collaborate to co-develop deep learning-enabled technologies to facilitate expedited pathology analytics, and Charles River will serve as the sole contract research organisation providing the Patholytix preclinical solution to clients._ ## **HERG Screening Market Segmentation** ### **HERG Screening Type Outlook** ### **HERG Screening Ion Channel Outlook** ### **HERG Screening Application Outlook** ### **HERG Screening Regional Outlook** ## Market Drivers ### Growing Investment in Pharmaceutical R&D The HERG Screening Market is benefiting from a surge in investment directed towards pharmaceutical research and development. As companies strive to innovate and bring new therapies to market, the need for effective HERG screening becomes increasingly critical. In 2025, pharmaceutical R&D spending is projected to exceed USD 200 billion, with a substantial portion allocated to safety assessments, including HERG testing. This influx of funding is likely to enhance the capabilities of HERG screening technologies and expand the market. Furthermore, the competitive landscape in the pharmaceutical sector is pushing companies to adopt rigorous screening protocols to ensure the safety and efficacy of their products. ### Rising Demand for Cardiotoxicity Testing The HERG Screening Market is experiencing a notable increase in demand for cardiotoxicity testing, driven by the need for safer pharmaceuticals. As drug development progresses, the identification of potential cardiac risks associated with new compounds has become paramount. Regulatory agencies are emphasizing the importance of thorough cardiac safety assessments, which has led to a surge in the adoption of HERG screening methods. In 2025, the market for cardiotoxicity testing is projected to reach approximately USD 1.5 billion, reflecting a compound annual growth rate of around 8%. This trend indicates a growing recognition of the need for effective HERG screening to mitigate risks associated with drug-induced arrhythmias. ### Collaborative Efforts in Drug Development The HERG Screening Market is witnessing a rise in collaborative efforts among pharmaceutical companies, academic institutions, and regulatory agencies. These partnerships aim to enhance the understanding of cardiac safety and improve HERG screening methodologies. Collaborative research initiatives are fostering innovation and knowledge sharing, which is essential for advancing HERG testing techniques. As these collaborations gain momentum, they are expected to lead to the development of standardized protocols and best practices in HERG screening. This trend not only enhances the credibility of HERG testing but also promotes a more efficient drug development process, ultimately benefiting the industry as a whole. ### Increased Focus on Drug Safety Regulations The HERG Screening Market is significantly influenced by the evolving landscape of drug safety regulations. Regulatory bodies are increasingly mandating comprehensive cardiac safety evaluations for new drug candidates, which has heightened the importance of HERG screening. In recent years, there has been a marked shift towards stricter guidelines, compelling pharmaceutical companies to prioritize HERG testing in their development pipelines. This regulatory pressure is expected to propel the HERG screening market, with estimates suggesting a market value of USD 1.2 billion by 2025. The emphasis on compliance and safety is likely to drive investments in HERG screening technologies and services. ### Technological Innovations in Screening Methods Technological advancements are significantly shaping the HERG Screening Market, as new methodologies and tools emerge to enhance screening efficiency and accuracy. Innovations such as high-throughput screening and automated patch-clamp systems are streamlining the process of assessing HERG channel activity. These advancements not only reduce the time required for testing but also improve the reliability of results. The integration of artificial intelligence and machine learning into screening processes is also gaining traction, potentially revolutionizing data analysis and interpretation. As these technologies continue to evolve, they are likely to attract investment and drive growth within the HERG screening sector. ## Future Outlook The HERG Screening Market is projected to grow at 11.04% CAGR from 2025 to 2035, driven by increasing regulatory demands and advancements in drug development technologies. **New opportunities:** - Integration of AI-driven predictive analytics for HERG risk assessment. Development of high-throughput screening platforms to enhance efficiency. Expansion into emerging markets with tailored HERG screening solutions. By 2035, the HERG Screening Market is expected to be robust, driven by innovation and strategic expansion. ## Segment Insights ### By Type: Gene KCNH2 (Largest) vs. Mutant KCNH2 (Fastest-Growing) In the HERG Screening Market, the Gene KCNH2 segment holds a substantial share, reflecting its established presence and critical importance in drug development and screening processes. As a key player in the ion channel research, Gene KCNH2 attracts major investments and attention within the pharmaceutical industry. Conversely, the Mutant KCNH2 segment, while currently smaller in market share, is rapidly gaining ground. This surge in interest can be attributed to the increasing focus on personalized medicine and the identification of specific mutations that can influence drug efficacy and safety. Gene KCNH2 (Dominant) vs. Mutant KCNH2 (Emerging) The Gene KCNH2 segment is a dominant force within the HERG Screening Market, known for its robust application in pharmacological research and testing for cardiac safety profiles. It is critical in identifying cardiac risks associated with drug candidates before clinical trials, positioning it as a standard for regulatory compliance. On the other hand, the Mutant KCNH2 segment is gaining prominence as more researchers explore the implications of genetic variations on drug responses. This emerging focus is driven by advancements in genomic medicine, which foster a greater understanding of how specific mutations can impact individual patient outcomes in drug therapy, thereby widening the scope for innovative and tailored treatment options. ### By Ion Channel: Voltage Gated (Largest) vs. Ligand Gated (Fastest-Growing) In the HERG Screening Market, the Voltage Gated ion channels hold the largest market share, driven by their critical role in cardiac safety assessments during drug development. Their established importance has allowed them to dominate the market landscape, with many pharmaceutical companies relying on these channels for predictive electrophysiology models. Conversely, Ligand Gated channels, while currently smaller in market share, are rapidly gaining traction due to advancements in [drug discovery](https://www.marketresearchfuture.com/reports/drug-discovery-services-market-5870) technologies that enhance their testing reliability and relevance. Ion Channels: Voltage Gated (Dominant) vs. Ligand Gated (Emerging) Voltage Gated ion channels are critical components in the HERG Screening Market, characterized by their response to membrane potential changes and pivotal role in heart rhythm regulation. They are extensively utilized due to their proven reliability in predicting cardiotoxicity, thus appealing to pharma and biotech firms. On the other hand, Ligand Gated channels are emerging as a vital segment within the market. Their ability to respond to specific neurotransmitters makes them increasingly important in drug development, particularly in neurology and psychiatry therapeutics, positioning them as a promising area of growth in the coming years. ### By Application: Antiarrhythmic (Largest) vs. Antipsychotic (Fastest-Growing) The HERG Screening Market exhibits a diverse application landscape, with the Antiarrhythmic segment capturing the largest market share. Antiarrhythmic drugs are pivotal in managing heart rhythm disorders, leading to their significant presence and demand in HERG screening activities. Following behind, the Antipsychotic segment, while smaller in share, is rapidly gaining traction due to increasing awareness of mental health and the need for effective treatment options. The Antibiotics and 'Others' categories maintain niche roles within the market, contributing to the overall diversity of applications. Antiarrhythmic (Dominant) vs. Antipsychotic (Emerging) Within the HERG Screening Market, the Antiarrhythmic segment stands out as the dominant player, driven by its crucial role in addressing critical cardiac conditions. These drugs are central to safe drug development, especially in cardiotoxicity assessments. Conversely, the Antipsychotic segment is emerging as a fast-growing force. This surge is fueled by increasing mental health challenges, prompting a need for rigorous screening to ensure the safety and efficacy of new antipsychotic medications. As regulatory mechanisms tighten, both segments highlight unique requirements in drug testing and compliance, shaping their future roles in the HERG screening landscape. ## Regional Market Share Analysis ### North America : Leading Innovation and Research North America is the largest market for HERG screening, accounting for approximately 45% of the global share. The region's growth is driven by advanced research facilities, increasing R&D investments, and stringent regulatory requirements that emphasize drug safety. The demand for HERG screening is further fueled by the rising prevalence of cardiovascular diseases and the need for effective drug development processes. The United States is the primary contributor, with key players like Thermo Fisher Scientific and Charles River Laboratories leading the market. The competitive landscape is characterized by a focus on technological advancements and collaborations among major firms. Canada also plays a significant role, contributing to the market with its growing biopharmaceutical sector and supportive regulatory environment. ### Europe : Regulatory Framework and Growth Europe is the second-largest market for HERG screening, holding around 30% of the global market share. The region benefits from a robust regulatory framework that mandates comprehensive safety assessments for new drugs, driving the demand for HERG screening services. The increasing focus on personalized medicine and the rise in clinical trials are also significant growth drivers. Germany and the United Kingdom are the leading countries in this market, with a strong presence of key players like Evotec SE and Celerion. The competitive landscape is marked by collaborations between pharmaceutical companies and research organizations, enhancing innovation in HERG screening methodologies. The European Medicines Agency continues to play a crucial role in shaping the regulatory landscape, ensuring drug safety and efficacy. ### Asia-Pacific : Rapidly Growing Market Potential Asia-Pacific is witnessing significant growth in the HERG screening market, accounting for approximately 20% of the global share. The region's expansion is driven by increasing investments in healthcare infrastructure, a growing number of clinical trials, and rising awareness of drug safety. Countries like China and India are emerging as key players, supported by favorable government initiatives and a burgeoning pharmaceutical sector. China is leading the market, with a surge in biopharmaceutical research and development activities. The competitive landscape is evolving, with both local and international companies vying for market share. Key players such as BioAgilytix and Inotiv are establishing a strong foothold, contributing to the region's growth in HERG screening services. The increasing collaboration between academia and industry is also fostering innovation in this space. ### Middle East and Africa : Untapped Market Opportunities The Middle East and Africa represent an emerging market for HERG screening, holding about 5% of the global share. The growth in this region is primarily driven by increasing healthcare investments, rising awareness of drug safety, and the need for regulatory compliance in drug development. Countries like South Africa and the UAE are beginning to establish themselves as key players in the pharmaceutical sector, creating demand for HERG screening services. The competitive landscape is still developing, with a mix of local and international companies entering the market. The presence of key players is gradually increasing, and collaborations with global firms are expected to enhance the region's capabilities in HERG screening. As regulatory frameworks become more established, the market is poised for significant growth in the coming years. ## Competitive Benchmarking The HERG Screening Market is currently characterized by a dynamic competitive landscape, driven by the increasing demand for safety assessments in drug development. Key players are focusing on innovation and strategic partnerships to enhance their service offerings and maintain a competitive edge. Companies such as Thermo Fisher Scientific (US), Charles River Laboratories (US), and Evotec SE (DE) are at the forefront, leveraging their technological capabilities and extensive experience in the field. Their operational focus appears to be on integrating advanced technologies and expanding their global footprint, which collectively shapes a competitive environment that is both robust and evolving.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing their supply chains to enhance efficiency and responsiveness to market demands. The HERG Screening Market is moderately fragmented, with several players vying for market share. However, the influence of major companies like BioAgilytix (US) and Celerion (US) is notable, as they continue to set benchmarks for quality and innovation in screening services, thereby impacting the overall market structure. In August Thermo Fisher Scientific (US) announced the launch of a new high-throughput HERG screening platform designed to accelerate drug development timelines. This strategic move is significant as it not only enhances their product portfolio but also positions them as a leader in providing rapid and reliable screening solutions, which is increasingly critical in the fast-paced pharmaceutical industry. The introduction of this platform is likely to attract a broader client base seeking efficiency in their drug development processes. In September Charles River Laboratories (US) expanded its collaboration with a leading biopharmaceutical company to enhance HERG screening capabilities. This partnership is indicative of a trend towards collaborative innovation, allowing both entities to leverage their strengths in drug safety assessments. Such strategic alliances are essential for fostering advancements in screening technologies and ensuring compliance with regulatory standards, which are becoming more stringent. In July Evotec SE (DE) entered into a strategic partnership with a technology firm to integrate artificial intelligence into their HERG screening processes. This initiative is particularly noteworthy as it reflects a broader trend towards digital transformation within the industry. By harnessing AI, Evotec aims to improve the accuracy and efficiency of their screening services, thereby enhancing their competitive positioning in a market that increasingly values technological integration. As of October the HERG Screening Market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are playing a crucial role in shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, it is anticipated that competitive differentiation will increasingly hinge on innovation and technological advancements rather than solely on price. Companies that prioritize supply chain reliability and invest in cutting-edge technologies are likely to emerge as leaders in this evolving market. ## Recent News & Developments _**March 2020:**An alliance was formed between Charles River Laboratories and Deciphex, a pioneer in preclinical_[_digital pathology_](https://www.marketresearchfuture.com/reports/digital-pathology-market-1955)_software-as-a-service. The organisations will collaborate to co-develop deep learning-enabled technologies to facilitate expedited pathology analytics, and Charles River will serve as the sole contract research organisation providing the Patholytix preclinical solution to clients._ ## Report Scope | MARKET SIZE 2024 | 1.12(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 1.244(USD Billion) | | MARKET SIZE 2035 | 3.545(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.04% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Thermo Fisher Scientific (US), Charles River Laboratories (US), Evotec SE (DE), Celerion (US), Crown Bioscience (US), BioAgilytix (US), Inotiv (US), Haplogen (US) | | Segments Covered | Type, Ion Channel, Application, Region | | Key Market Opportunities | Advancements in high-throughput screening technologies enhance efficiency in HERG Screening Market assessments. | | Key Market Dynamics | Rising regulatory scrutiny drives demand for advanced HERG screening technologies in pharmaceutical development. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the HERG Screening Market as of 2024?** A: The HERG Screening Market was valued at 1.12 USD Billion in 2024. **Q: What is the projected market size for the HERG Screening Market in 2035?** A: The HERG Screening Market is projected to reach 3.545 USD Billion by 2035. **Q: What is the expected CAGR for the HERG Screening Market during the forecast period 2025 - 2035?** A: The expected CAGR for the HERG Screening Market during the forecast period 2025 - 2035 is 11.04%. **Q: Which companies are considered key players in the HERG Screening Market?** A: Key players in the HERG Screening Market include Thermo Fisher Scientific, Charles River Laboratories, Evotec SE, and others. **Q: What are the main segments of the HERG Screening Market?** A: The main segments of the HERG Screening Market include Type, Ion Channel, and Application. **Q: What was the market valuation for the Gene KCNH2 segment in 2024?** A: The market valuation for the Gene KCNH2 segment was 0.672 USD Billion in 2024. **Q: How does the valuation of the Mutant KCNH2 segment compare to the Gene KCNH2 segment?** A: The Mutant KCNH2 segment was valued at 0.448 USD Billion in 2024, which is lower than the Gene KCNH2 segment. **Q: What is the projected valuation for the Voltage Gated ion channel segment by 2035?** A: The Voltage Gated ion channel segment is projected to reach 1.99 USD Billion by 2035. **Q: Which application segment is expected to show the highest growth in the HERG Screening Market?** A: The Antiarrhythmic application segment is expected to show the highest growth, projected to reach 1.45 USD Billion by 2035. **Q: What is the expected market performance for the Antibiotics application segment by 2035?** A: The Antibiotics application segment is projected to reach 0.7 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/herg-screening-market-10386*